Sarrazin, C
905  Ergebnisse:
Personensuche X
?
1

Strategietreffen: Virushepatitis in Deutschland eliminieren..:

Tergast, T. L. ; Protzer, U. ; Zeuzem, S....
Zeitschrift für Gastroenterologie.  61 (2023)  2 - p. 198-201 , 2023
 
?
2

Physica status solidi 

Volume 107, Number 2: June 16  Physica status solidi ; Volume 107, Number 2, A
Adán, A ; Akimov, A. I ; Baran, M... - Reprint 2021 . , [2022]
 
?
 
?
5

Editorial: HBsAg serum levels in HBeAg‐negative chronic HBV..:

Kuhnhenn, L. ; Jiang, B. ; Kubesch, A....
Alimentary Pharmacology & Therapeutics.  48 (2018)  1 - p. 103-104 , 2018
 
?
6

Impact of HBV genotype and mutations on HBV DNA and qHBsAg ..:

Kuhnhenn, L. ; Jiang, B. ; Kubesch, A....
Alimentary Pharmacology & Therapeutics.  47 (2018)  11 - p. 1523-1535 , 2018
 
?
7

Editorial: genotype 3 HCV—who still needs ribavirin in a pa..:

von Felden, J. ; Vermehren, J. ; Schulze zur Wiesch, J...
Alimentary Pharmacology & Therapeutics.  47 (2018)  11 - p. 1550-1551 , 2018
 
?
11

A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ER..:

Almarzooqi, S ; van Tilborg, M ; Maan, R...
Journal of the Canadian Association of Gastroenterology.  1 (2018)  suppl_1 - p. 305-306 , 2018
 
?
12

Letter: impact of HBV genotypes and PC/BCP mutations on ser..:

Kuhnhenn, L. ; Jiang, B. ; Kubesch, A....
Alimentary Pharmacology & Therapeutics.  48 (2018)  2 - p. 238-239 , 2018
 
?
14

High efficacy of sofosbuvir/velpatasvir and impact of basel..:

von Felden, J. ; Vermehren, J. ; Ingiliz, P....
Alimentary Pharmacology & Therapeutics.  47 (2018)  9 - p. 1288-1295 , 2018
 
?
15

Time to viral suppression does not impact SVR in patients t..:

Sarrazin, C. ; Tran, T. ; Dylla, D....
Journal of Hepatology.  68 (2018)  - p. S302-S303 , 2018
 
1-15